- Drugs
- Wednesday, 15 Jul 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
The collaboration is part of the U.S. government’s Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.
AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.
The agreement includes an expansive study of trial participants and will use IQVIA’s virtual trial solutions that would make parts of the study remote.
Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.
Related Industry Updates
Sarcopenia Treatment Market is expected to reach US$ 5,264.76 million by 2030
Dec 01, 2023
OTC Drug and Dietary Supplement Market Outlook, Geographical Segmentation, Industry Size & Share, Comprehensive Analysis to 2027
Sep 09, 2020
Small Cell Lung Cancer (SCLC) Treatment Market is expected to reach US$ 9,173.60 million by 2030
Dec 21, 2023
COVID-19 Fallout Drives Major Increases for Driven's Online Cannabis Sales
Mar 17, 2020
Asia and Africa Lateral Flow Assay Market is expected to reach US$ 2,159.62 million by 2028
May 23, 2023
US Mail Order Pharmacy Market is expected to reach US$ 1,71,883.03 million by 2030
Oct 16, 2023
China Transmucosal Drug Delivery Systems Market Research With Size, Growth, Manufacturers, Segments And 2027 | 3M, Acrux, GW Pharmaceuticals
Feb 05, 2021
Follow us on
